3Somani P, Freimer E, Gross M, et al. Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis[J]. Antimicrobial Agents and Chemotherapy, 1988,32:530.
4Sharon RS, Glenn RH. The neurotoxicity of antibacterial agents[J]. An Internal Med, 1984, 101:92.
5Aronoff GR, Brier ME, Erbeck KM, et al. Drug dosing in dialysis patients. In: Owen WF, Pereira BG, Sayegh MH, eds. Dialysis and Transplantation[M]. 2001:358-372.
6Martinez-Rodriguez JE, Barriga F J, Santamaria J, et al.Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure [J]. Am J Med,2001, 111:115.
7Jackson GD, Berkovic SF. Ceftazidime encephalopathy:absence status and toxic hallucinations [J]. J Neurol Neurosurg Psychiatry, 1992, 55: 333.
8Verbish L, Verpooten GA, Guiliano RA, et al. Pharmacokinetics and tolerance after repeated doses of imipenem/cilastatin in patients with severe renal failure[J]. J Antimicrob Chemother, 1986, 18(suppl):E115.
9HUANG CK, CHEN YS, LEE SS, et al. Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections[J]. J Microbiol Immunol infect, 2002,35 (3) : 159-167.
10WUST J, FREI R. Multicenter study of the in vitro activity of cefepime in comparison with five other broad-spectrum antibiotics against clinical isolates of Gram-positive and Gram-negative bacteria from hospitalized patients in Switzerland[J]. Clin Microbiol Infect, 1999,5(5):262-269.
